Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

NCT06177067 is registered in ClinicalTrials.gov with St. Jude Children's Research Hospital as lead sponsor.

NCT NCT06177067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06177067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Lead sponsor
St. Jude Children's Research Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
April 19, 2024
Completion date
April 30, 2027
Enrollment
24 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia of ambiguous lineage, refractory acute myeloid leukemia, relapsed acute myeloid leukemia